Cancer Research UK would like to thank the following organisations for their support, without which the Scotland Against Cancer conference would not be possible. All Gold and Silver sponsors have a medical expertise and a commercial interest in cancer, but have not been involved in the content of this conference.


This group feeds back to MSPs interested in cancer issues in the Cross Party Group on Cancer in the Scottish Parliament. The Scottish Parliament’s Cross Party Group on Cancer uses the conference to help shape their programme of work.
Core sponsors are invited to contribute either as a ‘Gold’ sponsor or ‘Silver’ sponsor, as defined below:
Cost: £5,000 plus VAT
Note: Gold Sponsors are required to submit their logo on application.
Cost: £1,500 plus VAT
The conference is aimed at people working in politics, the health professions, patient representatives, health service managers, research scientists and other business groups with an interest in cancer and cancer issues:
Delegates usually form a good cross-section of people who can contribute to an organised forum on the care, treatment and outcome for people diagnosed with or at risk of developing cancer.
It is anticipated at around 200 delegates will attend. The conference organisers are aiming for sponsorship to fund around half of the cost of the conference – the rest being met by delegate fees.
Delegate fees are set at £80 for NHS Health Professional and Public Sector Bodies, £70 for the voluntary sector, £100 for commercial /private sector [except sponsors] – with a lower rate of £40 for patients / support group representatives / carers (there will also be some complimentary registrations available for this group).
The plenary session speakers and delegates in the subsequent discussion groups will consider the recently published Better Cancer Care: An Action Plan, reflect on recent achievements and discuss challenges for the future. The conference will consider the need for new ways of communicating prevention messages, the prospect of more accurate diagnoses, the need for new therapies and integration of services, and the strengths and weaknesses of cancer policy to meet and fund new challenges.
Topics have been arranged into these key issues -